4:19
News Detail
TI
Madrigal Pharmaceuticals raised $239 ml in gross equity from equity securities issuances and additional $50 mln in liquidity commitments
4:18 PM ET 12/21/2022 | Briefing.com
MDGL
Co announces that it has raised $259 million in gross equity (or $255 million in net proceeds) from equity securities issuances and an additional $50 million in liquidity commitments following the achievement of the clinical milestone under its Hercules Credit
Facility.Madrigal has completed $159 million in gross sales of common stock under its ATM Program ("ATM
Sales") and has separately entered into a $100 million definitive securities purchase agreement with two of its existing institutional investors for the purchase of $90 million in shares of Series B Convertible Preferred
Stock (the "Series B") and $10 million in shares of the Company's common stock.In connection with Madrigal's December 19, 2022 announcement of positive topline data from its pivotal Phase 3
MAESTRO-NASH clinical trial of resmetirom, Hercules Capital, Inc. (HTGC) confirmed that Madrigal has achieved its clinical milestone under the Company's Credit Facility with Hercules, thereby enabling Madrigal to draw upon a $50 million clinical milestone tranche over the next three months.
Recent MDGL News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/24/2025 08:45:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/24/2025 08:42:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/24/2025 08:39:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/24/2025 08:34:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/24/2025 08:30:12 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 06/20/2025 08:22:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2025 08:04:08 PM
- Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis • GlobeNewswire Inc. • 06/20/2025 10:30:32 AM
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 06/17/2025 08:05:00 PM
- Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference • GlobeNewswire Inc. • 06/02/2025 12:00:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/14/2025 04:15:20 PM
- Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis • GlobeNewswire Inc. • 05/10/2025 11:15:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/01/2025 12:53:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/01/2025 11:02:50 AM
- Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates • GlobeNewswire Inc. • 05/01/2025 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/29/2025 08:21:46 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/29/2025 08:16:49 PM
- Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress • GlobeNewswire Inc. • 04/29/2025 12:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2025 09:03:13 PM
- Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 • GlobeNewswire Inc. • 04/18/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/17/2025 08:52:52 PM
- Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer • GlobeNewswire Inc. • 04/16/2025 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/12/2025 08:32:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/12/2025 08:29:06 PM
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • CLDI • Jul 7, 2025 9:00 AM
VAYK Discloses More Insider Buying Approaching 15 Million • VAYK • Jul 2, 2025 10:37 AM
Patented, Groundbreaking Blockchain for Public Companies 'BlackStar Digital Trading PlatformTM' can Facilitate U.S. Registered Securities to Trade on Blockchain Without Tokens. • BEGI • Jul 1, 2025 12:54 PM
UC Asset (UCASU) Public Offering's Acquisition Target Reported Better Results • UCASU • Jul 1, 2025 9:15 AM
One World Products, Inc. Appoints William Rowland as Chief Financial Officer • OWPC • Jul 1, 2025 9:14 AM
Envirotech Begins Delivery of Bumble Bee Electric School Bus Units with First Three Texas Orders • EVTV • Jul 1, 2025 9:01 AM